Business
Curis Reports Second Quarter 2022 Financial Results and Business Update
Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential
About this update from Curis, Inc.
[{"type":"text","content":"Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)\nAppointed Industry Veteran Diantha Duvall as Chief Financial Officer\nStrong balance sheet with $107.2 million in cash and investments as of June 30, 2022; cash runway into 2024\nManagement to host conference call today at 4:30 p.m. ET\nLEXINGTON, Mass., Aug. 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2022 and provided business updates.\n\n \n \n \n \n \n \n\n \n\"This quarter, we issued the noteworthy first release of data from the TakeAim Lymphoma trial's combination arm that examined emavusertib combined with ibrutinib in B cell malignancies. This data showed tumor reduction in 8 of 9 evaluable patients, and the potential to help patients experiencing ibrutinib resistance. We look forward to continuing the advancement of our first-in-class, small molecule IRAK4 inhibitor in nine distinct patient populations across acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and B cell cancers. On the administrative front, I am also pleased to announce the appointment of Diantha Duvall as our new Chief Financial Officer. Diantha brings a wealth of experience from senior roles at Merck, Biogen, Bioverativ, Genocea and PricewaterhouseCoopers. We look forward to her contributions to the Curis mission,\" said James Dentzer, President and Chief Executive Officer of Curis.\n\"I am excited to join Curis at this critical time for the company,\" said Ms. Duvall. \"I found Curis to be particularly compelling due to its novel, targeted approach and pipeline of first-in-class cancer therapeutics with significant potential in areas of unmet need. I look forward to supporting the Curis team's mission to develop innovative and differentiated therapeutics that improve the lives of cancer patients.\"\nSecond Quarter 2022 and Recent Operational Highlights\nPrecision oncology, emavusertib (IRAK4 Inhibitor; Aurigene collaboration):\nThe company presented the first preliminary dataset from the comb...